On April 28, Teva declared a cash dividend of $0.34 for 1Q15, a positive for long-term investors. It repurchased ~8 million shares for $0.4 billion in 1Q15.
Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.
Teva’s new drug application for ProAir RespiClick was approved, with an expected launch of 2Q15. ProAir is the first breath-actuated dry-powder inhaler used to treat acute asthma symptoms.
In 1Q15, Teva beat Wall Street analysts’ revenue estimates of $4.81 billion, posting revenues of $4.98 million, an increase of ~3.5%.
Teva beat Wall Street adjusted EPS estimates of $1.25 by a wide margin, posting $1.36 EPS. This represents a growth of ~9%.
Pfizer slashed its reported revenue range by $500 million. Yet the estimated negative impact of foreign exchange is more than $500 million.
Pfizer is on a fast track to return value to its shareholders. In 1Q15, the company repurchased $6 billion of common stock.
Pfizer’s revenues from the Established Products segment declined 16% in 1Q15. This was primarily due to increasing generic competition.
Prevnar 13 is a vaccine used to treat adults with pneumococcal disease, including pneumonia. Global revenues from the drug grew by 48%.
A lower effective tax rate and share repurchases had a positive impact on EPS. The company has consistently beaten Wall Street analysts’ EPS estimates for the last eight quarters.
Though Centene’s EBITDA margins remained at 2.8% in both 1Q14 and 1Q15, they declined sequentially from 4.6% in 4Q14.
By the end of 1Q15, Centene (CNC) offered health insurance services to about 184,000 dual eligible members.
In 1Q15, Centene served about 161,700 members across 11 states through the public exchanges, which was a rise of 307.3% from the 39,700 members the company served in 1Q14.
Centene’s premium and service revenues increased by 42% from $3.35 billion in 1Q14 to $4.76 billion in 1Q15.
Centene (CNC) posted its 1Q15 earnings on April 28, 2015. The company beat the Wall Street diluted EPS estimates of $0.49 with a posted EPS of $0.52.
Aetna’s EBITDA margins rose from 10.6% in 1Q14 to 11.3% in 1Q15. Enrollment growth and an effective cost optimization strategy led to the high margins.
Aetna’s (AET) revenues from commercial enrollments increased by 5.8% in 1Q15. Public exchange membership was the primary driver of this growth.
As part of its payment strategy, Aetna projects its value-based spending as part of its total spending to rise from 25% in 2014 to 75% in 2020.
Aetna’s revenues from government-sponsored enrollments increased 12.4% in 1Q15. Total government enrollments increased sequentially by 85,000 members.
Aetna (AET) announced its 1Q15 earnings on April 28, 2015. The company posted EPS of $2.30, beating Wall Street EPS estimates of $1.94.